
Tuesday, October 18, 2022 5:16:37 PM
https://investors.immatics.com/static-files/0df36fcf-308b-4e29-afe7-c83c562abab6
Looks excellent imo.

Liked By
Spread the love. Be the first to like this post!
Recent IMTX News
- Annual and Transition Report (foreign Private Issuer) (20-f) • Edgar (US Regulatory) • 03/22/2023 10:57:22 AM
- Immatics Announces Full Year 2022 Financial Results and Corporate Update • GlobeNewswire Inc. • 03/21/2023 11:31:38 AM
- Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) • Edgar (US Regulatory) • 03/13/2023 10:31:17 AM
- Amended Statement of Ownership (sc 13g/a) • Edgar (US Regulatory) • 02/14/2023 10:24:03 PM
- Amended Statement of Ownership (sc 13g/a) • Edgar (US Regulatory) • 02/14/2023 09:02:47 PM
- Schedule 13g<br /> (sc 13g) • Edgar (US Regulatory) • 02/07/2023 11:07:40 AM
- Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) • Edgar (US Regulatory) • 01/09/2023 12:07:26 PM
- SVB Securities Sticks to Their Buy Rating for Immatics (IMTX) • TipRanks • 11/21/2022 04:15:41 AM
- Chardan Capital Sticks to Their Buy Rating for Immatics (IMTX) • TipRanks • 11/17/2022 11:15:19 PM
- Immatics Announces Third Quarter 2022 Financial Results and Business Update • GlobeNewswire Inc. • 11/17/2022 12:00:00 PM
- Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) • Edgar (US Regulatory) • 11/10/2022 02:12:01 PM
- Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) • Edgar (US Regulatory) • 10/18/2022 12:07:11 PM
- Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) • Edgar (US Regulatory) • 10/11/2022 10:31:44 AM
- Immatics Rises on $110M Underwritten Offering • TipRanks • 10/10/2022 01:28:02 PM
- Immatics Announces $110 Million Underwritten Offering of Ordinary Shares • GlobeNewswire Inc. • 10/10/2022 11:37:42 AM
- Immatics Reports Interim Clinical Data Update on ACTengine® IMA203 TCR-T Monotherapy Targeting PRAME • GlobeNewswire Inc. • 10/10/2022 11:36:02 AM
- SVB Securities Remains a Buy on Immatics (IMTX) • TipRanks • 09/14/2022 03:45:55 AM
- Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) • Edgar (US Regulatory) • 09/12/2022 11:01:18 AM
- Analysts Offer Insights on Healthcare Companies: Immatics (IMTX), Biogen (BIIB) and Bicycle Therapeutics (BCYC) • TipRanks • 09/11/2022 06:20:19 AM
- Immatics Presents Comprehensive Preclinical Data Set for TCR Bispecific Candidate IMA402 Targeting PRAME at European Society for Medical Oncology (ESMO) Congress 2022 • GlobeNewswire Inc. • 09/10/2022 07:06:16 AM
- SVB Securities Sticks to Its Buy Rating for Immatics (IMTX) • TipRanks • 09/07/2022 04:05:18 AM
- Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) • Edgar (US Regulatory) • 08/23/2022 11:13:27 AM
- Immatics Announces First Cancer Patient Treated with Second-Generation ACTengine® TCR-T Candidate IMA203CD8 Targeting PRAME • GlobeNewswire Inc. • 08/23/2022 11:00:00 AM
- SVB Securities Keeps Their Buy Rating on Immatics (IMTX) • TipRanks • 08/11/2022 03:16:13 AM
- Chardan Capital Remains a Buy on Immatics (IMTX) • TipRanks • 08/09/2022 10:35:12 PM
FEATURED Tiziana Life Sciences Announces Anti-CD3 mAb Research for the Treatment of Alzheimer's Disease to be Presented by Dr. Howard Weiner at the International Conference on Alzheimer's and Parkinson's Disease and Related Neurological Disorders Conference • Mar 31, 2023 7:07 AM
ILUS Confirms Further Funding Arrangements and Note Settlement • ILUS • Mar 31, 2023 10:21 AM
Sigyn Therapeutics Announces Filing of 2022 Annual Report on SEC Form 10-K • SIGY • Mar 31, 2023 10:06 AM
ARway Secures Multiple New SDK Deals to Drive Growth in $44B Indoor Positioning and Navigation Market • ARWYF • Mar 30, 2023 10:30 AM
Nextech3D.ai Enters Asian Market with Major 3D Modeling Deal to Revolutionize E-Commerce • NTAR • Mar 30, 2023 10:00 AM
OMID Posts 2022 Annual Report and Provides Update • OMID • Mar 30, 2023 9:15 AM